Somaye Karimi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Somaye Karimi has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Mitra Rafiee
Department of Immunology, School of Medicine, Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran.
2 shared publications - Atena Mansouri
Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran
1 shared publication - Fahimeh Ghasemi
Cellular and Molecular Research Centre and Department of Medical Biotechnology, Faculty of Medicine Birjand University of Medical Sciences Birjand Iran
1 shared publication - Fatemeh Nikoomanesh
Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran
1 shared publication - Mehdi Shakibaie
Pharmaceutical Sciences Research Center, Department of Pharmaceutics and Nanotechnology, School of Pharmacy, Birjand University of Medical Sciences, Birjand, Iran
1 shared publication - Mohammad Amin Abdolahi Ziaaldini
Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran
1 shared publication
Latest Publications
- Open Access
- 1 June 2026
- Published by InkVista Publishing House
- Vol. 33 (2) , 86-98
A review on the process immune system's interaction with mycobiota and pathogenic fungi
In recent years, the role of mycobiota as a fungal component of the human microbiota and its complex interactions with the immune system have become a major focus of immunology and infectious disease research. Increasing evidence suggests that mycobiota, in addition to maintaining mucosal homeostasis, plays a fundamental role in inducing immune tolerance, ...
- 1 June 2026
- Published by InkVista Publishing House
- Vol. 33 (2) , 86-98
Open AccessA review on the process immune system's interaction with mycobiota and pathogenic fungi
In recent years, the role of mycobiota as a fungal component of the human microbiota and its complex interactions with the immune system have become a major focus of immunology and infectious disease research. Increasing evidence suggests that mycobiota, in addition to maintaining mucosal homeostasis, plays a fundamental role in inducing immune tolerance, ...
- Open Access
- 1 January 2025
- Published by Wiley in Dermatology Research and Practice
- Vol. 2025 (1) , 9764336
Thymoquinone Inhibits Proliferation and Induces Apoptosis in Immortalized Keratinocytes via Upregulation of p53 Expression
Introduction: Psoriasis, as a common inflammatory skin disease, is characterized by hyperproliferation of epidermal keratinocytes and induction of an inflammatory response. Apoptosis induction and prevention of the proliferation of keratinocytes can help to treat and manage this disease. Thymoquinone (TQ), a bioactive compound with antioxidant and anti‐inflammatory properties, has also been reported as a natural antitumor agent. This study aimed to evaluate the effects of TQ on proliferation and apoptosis in human keratinocyte cells (HaCaT). Methods: HaCaT cells were treated with increasing concentrations of TQ (1, 2, 4, 6, 8, 16, 32, and 64 μg/mL), and cell viability was assessed using the MTT assay. Apoptosis was analyzed via flow cytometry using Annexin V‐FITC/PI staining. Expression levels of p53, Bax, and BCL‐xl genes were measured by real‐time PCR. Results: TQ significantly reduced cell viability in a dose‐dependent manner, with an IC50 of 11.64 μg/mL after 72 h. Flow cytometry revealed a marked increase in early apoptotic cells following treatment with 8 μg/mL TQ (41.00% ± 5.04%) compared to control (17.8% ± 2.26%, P ≤ 0.001). Gene expression analysis showed significant upregulation of p53, while Bax and BCL‐xl levels showed no significant changes. Conclusion: TQ induces apoptosis in human HaCaT cells primarily through p53‐dependent pathways, suggesting its potential as a therapeutic agent for skin‐related disorders .
- 1 January 2025
- Published by Wiley in Dermatology Research and Practice
- Vol. 2025 (1) , 9764336
Open AccessThymoquinone Inhibits Proliferation and Induces Apoptosis in Immortalized Keratinocytes via Upregulation of p53 Expression
Introduction: Psoriasis, as a common inflammatory skin disease, is characterized by hyperproliferation of epidermal keratinocytes and induction of an inflammatory response. Apoptosis induction and prevention of the proliferation of keratinocytes can help to treat and manage this disease. Thymoquinone (TQ), a bioactive compound with antioxidant and anti‐inflammatory properties, has also been reported as a natural antitumor agent. This study aimed to evaluate the effects of TQ on proliferation and apoptosis in human keratinocyte cells (HaCaT). Methods: HaCaT cells were treated with increasing concentrations of TQ (1, 2, 4, 6, 8, 16, 32, and 64 μg/mL), and cell viability was assessed using the MTT assay. Apoptosis was analyzed via flow cytometry using Annexin V‐FITC/PI staining. Expression levels of p53, Bax, and BCL‐xl genes were measured by real‐time PCR. Results: TQ significantly reduced cell viability in a dose‐dependent manner, with an IC50 of 11.64 μg/mL after 72 h. Flow cytometry revealed a marked increase in early apoptotic cells following treatment with 8 μg/mL TQ (41.00% ± 5.04%) compared to control (17.8% ± 2.26%, P ≤ 0.001). Gene expression analysis showed significant upregulation of p53, while Bax and BCL‐xl levels showed no significant changes. Conclusion: TQ induces apoptosis in human HaCaT cells primarily through p53‐dependent pathways, suggesting its potential as a therapeutic agent for skin‐related disorders .